Creative Planning lessened its position in shares of Colgate-Palmolive Company (NYSE:CL) by 5.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 96,157 shares of the company’s stock after selling 5,794 shares during the period. Creative Planning’s holdings in Colgate-Palmolive were worth $7,128,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the business. Blue Chip Partners Inc. lifted its stake in shares of Colgate-Palmolive by 0.4% during the first quarter. Blue Chip Partners Inc. now owns 1,805 shares of the company’s stock worth $132,000 after purchasing an additional 8 shares in the last quarter. M Holdings Securities Inc. lifted its stake in shares of Colgate-Palmolive by 0.4% during the first quarter. M Holdings Securities Inc. now owns 5,366 shares of the company’s stock worth $393,000 after purchasing an additional 21 shares in the last quarter. Capital Investment Advisors LLC lifted its stake in shares of Colgate-Palmolive by 0.3% during the second quarter. Capital Investment Advisors LLC now owns 8,318 shares of the company’s stock worth $617,000 after purchasing an additional 27 shares in the last quarter. Savant Capital LLC lifted its stake in shares of Colgate-Palmolive by 0.3% during the first quarter. Savant Capital LLC now owns 10,526 shares of the company’s stock worth $770,000 after purchasing an additional 30 shares in the last quarter. Finally, Smith Moore & CO. lifted its stake in shares of Colgate-Palmolive by 0.3% during the first quarter. Smith Moore & CO. now owns 10,373 shares of the company’s stock worth $759,000 after purchasing an additional 32 shares in the last quarter. 73.10% of the stock is owned by hedge funds and other institutional investors.

In related news, insider Patricia Verduin sold 3,833 shares of the stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $72.41, for a total value of $277,547.53. Following the completion of the sale, the insider now owns 53,022 shares in the company, valued at $3,839,323.02. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP John J. Huston sold 14,000 shares of the stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $71.36, for a total transaction of $999,040.00. Following the completion of the sale, the senior vice president now owns 88,598 shares of the company’s stock, valued at approximately $6,322,353.28. The disclosure for this sale can be found here. Insiders have sold 217,969 shares of company stock valued at $15,693,933 over the last 90 days. Corporate insiders own 1.02% of the company’s stock.

Colgate-Palmolive Company (NYSE:CL) traded up 3.60% on Monday, hitting $73.75. The company had a trading volume of 3,409,937 shares. The firm’s 50 day moving average price is $71.58 and its 200 day moving average price is $73.27. The stock has a market cap of $64.96 billion, a P/E ratio of 27.41 and a beta of 0.80. Colgate-Palmolive Company has a 12-month low of $63.43 and a 12-month high of $77.27.

Colgate-Palmolive (NYSE:CL) last released its quarterly earnings results on Friday, July 21st. The company reported $0.72 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.72. Colgate-Palmolive had a net margin of 15.83% and a return on equity of 3,121.95%. The company had revenue of $3.83 billion during the quarter, compared to analysts’ expectations of $3.89 billion. During the same period in the prior year, the company earned $0.70 earnings per share. The business’s quarterly revenue was down .5% compared to the same quarter last year. Equities analysts predict that Colgate-Palmolive Company will post $2.89 earnings per share for the current fiscal year.

A number of research analysts have commented on the company. Zacks Investment Research upgraded Colgate-Palmolive from a “hold” rating to a “buy” rating and set a $80.00 price objective on the stock in a research note on Monday. Morgan Stanley upgraded Colgate-Palmolive from an “equal weight” rating to an “overweight” rating in a research note on Monday. Macquarie assumed coverage on Colgate-Palmolive in a research note on Thursday, September 14th. They set a “neutral” rating and a $76.00 price objective on the stock. Jefferies Group LLC restated a “hold” rating and set a $79.00 price objective on shares of Colgate-Palmolive in a research note on Thursday, August 24th. Finally, Deutsche Bank AG restated a “hold” rating and set a $75.00 price objective on shares of Colgate-Palmolive in a research note on Monday, July 24th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $75.62.

ILLEGAL ACTIVITY NOTICE: “Creative Planning Lowers Holdings in Colgate-Palmolive Company (CL)” was first published by Watch List News and is owned by of Watch List News. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.watchlistnews.com/creative-planning-lowers-holdings-in-colgate-palmolive-company-cl/1587413.html.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company (Colgate) is a consumer products company. The Company operates in two product segments: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care product segment is operated through five geographic segments, which include North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.

Institutional Ownership by Quarter for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive Company and related companies with Analyst Ratings Network's FREE daily email newsletter.